Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HQL

HOLDREMOVE

Abrdn Life Sciences Investors · Financial Services · United States · $537M · Avg Vol: $2M/d

60
StockRank
Q
34
V
53
M
62
P/E (TTM)
2.6x
ROE
41.4%
D/E
Dividend %
11.3%
AI CONVICTION THESIS

Abrdn Life Sciences Investors is a closed-end fund with very low quality metrics, and we prefer owning concentrated, direct equity stakes rather than paying layered fees for a diversified fund.

COMPANY DESCRIPTION

abrdn Life Sciences Investors is a closed-end fund that invests in public and private companies within the life sciences industry, including biotechnology, pharmaceuticals, and medical devices. The fund's competitive advantage lies in its ability to invest a portion of its assets in venture-stage, privately held companies, offering retail investors rare access to early-stage healthcare innovations. It is managed by abrdn's specialized healthcare team, targeting long-term capital appreciation through a diversified portfolio of cutting-edge science companies.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue-103M24M87M86M91.6%
EPS2.66-4.260.793.044.6%
Shares26M27M28M30M+15.3%
Debt17M666,959888,6102M-53.2%
Equity398M402M460M514M8.9%
Op CF32M
Inv CF
Fin CF-32M
Loading...
PRICE (1M)+3.3%
16.5116.8717.2317.6017.96May 7May 29Jun 18
SMA 50SMA 200
Close
$17.96
RSI (14)
51.3
52W High
$18.14
From 52W High
1.0%

SCORE BREAKDOWN

Quality
34
ROIC (ROA)
-0.6%*8.1
ROE
41.4%97.0
GP/Assets
0.2%3.7
Op. Margin
-516.5%1.3
FCF/Assets
-0.8%21.9
Piotroski
68.0
Int. Cover
N/A
D/E Ratio
N/A
Current Ratio
1.61x49.1
Value
53
P/E (TTM)
2.6x97.6
EV/EBITDA
N/A
P/FCF
N/A
P/B
1.0x57.8
P/S
464.4x0.5
Div Yield
11.3%94.9
Momentum
62
52W High %
99%90.9
RS 6M
3%70.4
SMA 50/200
1.09x73.0
EPS Rev 4W
N/A
EPS Rev 12W
N/A
EPS Improve
N/A
Q Growth
N/A

FUNDAMENTALS

Market Cap
$537M
P/E (Forward)
Gross Margin
100.0%

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of HQL are excluded.

TickerCompanyMkt CapStockRankSignal
HQLAbrdn Life Sciences Investors(you)$537M60HOLD
NMCONuveen Municipal Credit Opportunities Fund$598M58HOLD
GUTThe Gabelli Utility Trust$558M63HOLD
BGYBlackRock Enhanced International Dividend Trust$522M55HOLD
FFAFirst Trust Enhanced Equity Income Fund$460M62HOLD
DSUBlackRock Debt Strategies Fund, Inc.$619M56HOLD
ECCEagle Point Credit Company$554M52HOLD
GAINGladstone Investment Corporation$587M67BUY
GLADGladstone Capital Corporation$437M54HOLD
FFCFlaherty & Crumrine Preferred Securities Income Fund Inc.$774M62HOLD

Peer medians: ROE 10.8% · P/E 13.6x · Gross margin 0.0%

Abrdn Life Sciences Investors (HQL) — Stock Score Summary

Abrdn Life Sciences Investors (HQL) has a MoatMap StockRank of 60/100 based on Quality (34/100), Value (53/100), and Momentum (62/100) factor scores. The current signal is HOLD. Abrdn Life Sciences Investors is a closed-end fund with very low quality metrics, and we prefer owning concentrated, direct equity stakes rather than paying layered fees for a diversified fund.

abrdn Life Sciences Investors is a closed-end fund that invests in public and private companies within the life sciences industry, including biotechnology, pharmaceuticals, and medical devices. The fund's competitive advantage lies in its ability to invest a portion of its assets in venture-stage, privately held companies, offering retail investors rare access to early-stage healthcare innovations. It is managed by abrdn's specialized healthcare team, targeting long-term capital appreciation through a diversified portfolio of cutting-edge science companies.

Key Financial Metrics

Price$17.96
Market Cap$537M
P/E (TTM)2.55
Price/Book0.98
Return on Equity41.4%
Gross Margin100.0%
Operating Margin-516.5%
Revenue Growth-60.8%
Dividend Yield11.3%
Free Cash Flow$-4M

Abrdn Life Sciences Investors operates in the Asset Management industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Abrdn Life Sciences Investors’s (HQL) StockRank?
MoatMap’s StockRank for Abrdn Life Sciences Investors (HQL) is 60/100, with a Hold signal. It is a composite of Quality (34), Value (53), and Momentum (62) factor ranks across MoatMap’s 20,000+ stock universe.
Does Abrdn Life Sciences Investors have an economic moat?
Abrdn Life Sciences Investors (HQL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Abrdn Life Sciences Investors a buy, hold, or sell?
MoatMap’s current signal for Abrdn Life Sciences Investors (HQL) is Hold, based on a StockRank of 60/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Abrdn Life Sciences Investors in?
Abrdn Life Sciences Investors (HQL) operates in the Financial Services sector, specifically the Asset Management industry (United States).